Arbutus announces pipeline updates and dosing of the first subject in the phase 1a/1b clinical trial with ab-101; cash runway extended

Progressing development of hepatitis b virus (hbv) compounds imdusiran (ab-729) and ab-101, an oral pd-l1 inhibitor

ABUS Ratings Summary

ABUS Quant Ranking